明德生物(002932) - 2025 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net profit of between 12 million to 18 million yuan for 2025, representing a decline of 75.85% to 83.90% compared to the previous year[4]. - The net profit attributable to shareholders is projected to decrease by over 50% year-on-year[2]. - The net profit after deducting non-recurring gains and losses is projected to be between -98 million to -78 million yuan, an increase of 30.17% to 44.42% compared to the previous year[4]. - Basic earnings per share are expected to be between 0.05 to 0.08 yuan, down from 0.33 yuan in the previous year[4]. Revenue and Income Changes - Government subsidies received decreased by over 40 million yuan compared to the same period last year[3]. - Investment income is expected to decline by over 30 million yuan year-on-year due to lower yields from financial products[3]. - The company anticipates a credit impairment loss increase due to lower collection of overdue receivables and reduced reversal of impairment provisions[3]. Operational Strategy and Caution - The company will continue to optimize product and customer structures while enhancing cost control and operational quality[5]. - This earnings forecast is based on preliminary calculations and has not been audited by an external auditor[6]. - Investors are advised to exercise caution and consider investment risks due to the preliminary nature of the financial data[6].